Exploration of Low-Abundance Tundrisphaera and Tissue 3-Hydroxybutyric Acid (β-HB) in Gastric Cancer Lymphovascular Invasion: A Multi- Cohort Multi-Omics Study with Clearly Defined Evidence Boundaries

Gastric cancer is a disease where cells in the stomach grow out of control, but the true danger often lies not in the size of the tumor itself, but in how it spreads. One of the earliest and most critical ways this cancer moves is through a process called lymphovascular invasion. This happens when cancer cells sneak into the tiny tubes that carry lymph fluid or blood, using them as highways to travel to other parts of the body. Once these cells enter these vessels, the outlook for the patient becomes much more serious. Scientists have long suspected that the microscopic world living inside our bodies, specifically the bacteria in our stomach tissue, might play a role in helping cancer cells make this dangerous journey. At the same time, they know that cancer cells change how they eat and burn energy, sometimes producing chemical byproducts called ketone bodies. The big question is whether these tiny bacteria and these chemical changes are connected, and if they work together to push cancer cells into the bloodstream.

A team of researchers set out to investigate this possibility by looking directly at stomach tissue samples from patients. They gathered a group of sixty-five patients who had undergone surgery for gastric cancer. For each patient, they had two types of detailed data: a map of the bacteria living in their tumor tissue and a chemical inventory of the small molecules found in that same tissue. They split these patients into two groups based on what the pathologists saw under a microscope: those whose cancer had not yet entered the blood or lymph vessels, and those whose cancer had already begun this invasion. The researchers wanted to see if the bacterial communities were different between these two groups and if the levels of a specific chemical, known as beta-hydroxybutyric acid, were higher in the tissues where the cancer was spreading.

When the scientists looked at the overall bacterial communities, they found that the two groups of patients were surprisingly similar. There was no massive shift in the types or numbers of bacteria that could clearly separate those with spreading cancer from those without. However, when they looked closer at specific, very rare types of bacteria, they found a few candidates that showed higher cumulative sequence counts in the tissues where the cancer had invaded the vessels. One of these rare bacteria, named Tundrisphaera, showed a cumulative count of 33 in the group with invading cancer compared to just 1 in the group without invasion. It is important to note that these counts represent the total number of bacterial sequences found across all samples in each group, not the number of individual patients who had the bacteria, and therefore do not indicate that the bacteria appeared more often in individual patients. It was an extremely rare organism, making up less than one hundredth of one percent of the total bacteria, yet its sequence abundance seemed to track with the spread of the disease.

Alongside this bacterial finding, the researchers measured the levels of beta-hydroxybutyric acid, a chemical that the body produces when it breaks down fats. They found that the tissues with invading cancer had higher levels of this chemical compared to the tissues without invasion. The difference was nominally higher, but because the study looked at hundreds of chemicals at once, the statistical certainty was not absolute, with a metabolome-wide false discovery rate of 0.9758. More importantly, when the researchers looked at the relationship between the rare bacteria and the chemical within the same patient samples, they discovered something unexpected. Instead of the bacteria producing the chemical, the two seemed to move in opposite directions. In patients where the rare bacteria were more abundant, the level of the chemical was lower, and vice versa. This suggests that if there is a connection between the two, it is not a simple case of the bacteria making the chemical to help the cancer spread.

To understand if these findings held up in a broader context, the team turned to large public databases containing genetic information from thousands of other cancer patients. They checked if the genes responsible for handling this chemical or for helping cancer cells invade were active in patients with similar disease patterns. The results were mixed. While genes related to the physical invasion of blood vessels and the breakdown of tissue were strongly linked to poorer survival rates in other large groups of patients, the genes related to the chemical metabolism did not show the same clear pattern. In fact, when they looked at a different type of molecular data called methylation, which acts like a switch for turning genes on or off, they found no evidence to support the idea that the chemical or the bacteria were driving the invasion in those other groups.

The study also looked at whether the cancer cells relied on specific genes to survive, using computer models to simulate what would happen if those genes were turned off. While they identified a few genes that might be worth studying further, the models did not show that the cancer was universally dependent on them. This means that while the rare bacteria and the chemical change are interesting observations found in this specific group of patients, they have not yet been proven to be the main cause of the cancer's spread. The researchers are careful to state that their findings are a starting point for further investigation rather than a final answer. They have identified a rare bacterium and a chemical signal that appear together with invasive cancer, but the exact nature of their relationship remains unclear. The work serves as a detailed map of what is present in the tissue, highlighting a few specific clues that future studies will need to follow up on with new experiments to see if they can confirm a cause-and-effect relationship.